AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9048271 — intervention group
Group type: COMPARATOR
Intervention: Standard oral azathioprine 100 mg (control)
Number of subjects: 30
Study 8104966 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg every 12 hours
Number of subjects: 15
Study 8104966 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 8 mg every 12 hours
Number of subjects: 15
Study 8104966 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine 12 mg every 12 hours
Number of subjects: 15
Study 8104966 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (both doses)
Number of subjects: 15
Study 8104966 — intervention group
Group type: COMPARATOR
Intervention: Azelastine and Chlorpheniramine
Number of subjects: 15
Study 3535933 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PAM plus 5-FU (PF)
Number of subjects: 0
Study 3535933 — intervention group
Group type: EXPERIMENTAL
Intervention: PF plus tamoxifen (PFT)
Number of subjects: 0
Study 3535933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors with ER or PR ≥ 10 fmol or good nuclear grade
Number of subjects: 0
Study 3535933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear grade in combination with either or both of the receptors
Number of subjects: 0
Study 3535933 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of favorable tumor prognostic indicators
Number of subjects: 0
Study 3535933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 0
Study 31629325 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Star Excursion Balance Test (mSEBT)
Number of subjects: 86
Study 31629325 — intervention group
Group type: COMPARATOR
Intervention: Y-Balance Test (YBT)
Number of subjects: 86
Study 30063470 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem-cell transplantation (HSCT)
Number of subjects: 75
Study 30063470 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses
Number of subjects: 75
Study 30063470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative regimens (various)
Number of subjects: 75
Study 30063470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab as a conditioning agent
Number of subjects: 75
Study 27334138 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU)
Number of subjects: 168
Study 27334138 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFAs (722 mg DHA)
Number of subjects: 168
Study 27334138 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU) + n-3 LCPUFAs (722 mg DHA)
Number of subjects: 168
Study 27334138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 27334138 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 168
Study 24836309 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 264
Study 24836309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 22691894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg for 6 days
Number of subjects: 18
Study 22691894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg for 3 days after 4 mg for 3 days
Number of subjects: 18
Study 22691894 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 days
Number of subjects: 18
Study 22691894 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 1 mg on day 6
Number of subjects: 18
Study 20082144 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus 5-FU/LV
Number of subjects: 2966
Study 20082144 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 2966
Study 18842795 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg as sulfate) and micronutrients 5 d/wk for 10 wk
Number of subjects: 54
Study 18842795 — intervention group
Group type: COMPARATOR
Intervention: Micronutrients alone 5 d/wk for 10 wk
Number of subjects: 54
Study 15655095 — intervention group
Group type: COMPARATOR
Intervention: Out-patient management by primary care physicians
Number of subjects: 2145
Study 15655095 — intervention group
Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 2145
Study 12192466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous citalopram
Number of subjects: 0
Study 11145369 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 1568
Study 11145369 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380S
Number of subjects: 1568
Study 8540873 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 200 micrograms via Breath‐A‐Tech spacer
Number of subjects: 27
Study 8540873 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 200 micrograms via Volumatic spacer
Number of subjects: 27
Study 8540873 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 1 mg in 2 mL saline via jet nebuliser
Number of subjects: 27
Study 8540873 — intervention group
Group type: COMPARATOR
Intervention: Breath‐A‐Tech spacer
Number of subjects: 27
Study 8540873 — intervention group
Group type: COMPARATOR
Intervention: Volumatic spacer
Number of subjects: 27
Study 1742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25
Study 1742775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7148373 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry combined with chest physical therapy
Number of subjects: 20
Study 7148373 — intervention group
Group type: COMPARATOR
Intervention: Chest physical therapy alone
Number of subjects: 20
Study 31607623 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and strength training program (group A), 3 times per week for 12 months
Number of subjects: 40
Study 31607623 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group B)
Number of subjects: 40
Study 28750640 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH (docetaxel, carboplatin, trastuzumab)
Number of subjects: 74
Study 28750640 — intervention group
Group type: EXPERIMENTAL
Intervention: TCL (docetaxel, carboplatin, lapatinib)
Number of subjects: 74
Study 28750640 — intervention group
Group type: EXPERIMENTAL
Intervention: TCHL (docetaxel, carboplatin, trastuzumab, lapatinib)
Number of subjects: 74
Study 25039260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight self-administered weekly treatments with an 810-nm home-use laser at 5.0-6.4 J cm(‐2)
Number of subjects: 36
Study 25039260 — intervention group
Group type: COMPARATOR
Intervention: Control group (zero treatments)
Number of subjects: 36
Study 23432535 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem supplement
Number of subjects: 120
Study 23432535 — intervention group
Group type: COMPARATOR
Intervention: Routine doses of tacrolimus (Control)
Number of subjects: 120
Study 23432535 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 polymorphism-guided dosing equation
Number of subjects: 120
Study 21226883 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction counselling plus free nicotine replacement therapy (NRT)
Number of subjects: 1154
Study 21226883 — intervention group
Group type: COMPARATOR
Intervention: Simple cessation advice
Number of subjects: 1154
Study 19964700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile diabetes management systems (telemonitoring)
Number of subjects: 0
Study 17626647 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific Flexima 8.3F pigtail nephrostomy tube #27‐180 (PIG)
Number of subjects: 18
Study 17626647 — intervention group
Group type: COMPARATOR
Intervention: Boston Scientific 8.2F nephroureteral stent #410‐126 (NUS)
Number of subjects: 18
Study 15625361 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (SRS)
Number of subjects: 64
Study 15625361 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 64
Study 15625361 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 64
Study 15625361 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT (part of SRS)
Number of subjects: 64
Study 15625361 — intervention group
Group type: EXPERIMENTAL
Intervention: Median metastasis size
Number of subjects: 64
Study 11975827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 22
Study 11975827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 9727686 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion therapy (amiodarone for restoration and maintenance of sinus rhythm)
Number of subjects: 0
Study 9727686 — intervention group
Group type: COMPARATOR
Intervention: Control of ventricular rate only (diltiazem as primary therapy)
Number of subjects: 0
Study 8535958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin ophthalmic ointment
Number of subjects: 13
Study 8535958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin ophthalmic solution
Number of subjects: 13
Study 2403734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (160 mg administered twice daily)
Number of subjects: 102
Study 2403734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sotalol (320 mg administered twice daily)
Number of subjects: 102
Study 2403734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 2403734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 102
Study 2403734 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 102
Study 721790 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (112.7 mg/day)
Number of subjects: 97
Study 721790 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (116.7 mg/day)
Number of subjects: 97
Study 30561284 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel handheld telehealth device (Tyto)
Number of subjects: 50
Study 30561284 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone digital examination devices (stethoscope and otoscope)
Number of subjects: 50
Study 28193533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mode NIBS with high-frequency rTMS and tDCS
Number of subjects: 32
Study 28193533 — intervention group
Group type: COMPARATOR
Intervention: rTMS alone with sham tDCS
Number of subjects: 32
Study 26503099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 100
Study 26503099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23704677 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with type 2 diabetes
Number of subjects: 517
Study 23704677 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, diabetes duration, and mean HbA1c
Number of subjects: 517
Study 23704677 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest BMI tertile
Number of subjects: 517
Study 22208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Being forgotten (Study 1)
Number of subjects: 143
Study 22208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Being forgotten (Study 2)
Number of subjects: 143
Study 22208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Being remembered (Study 2)
Number of subjects: 143
Study 22208108 — intervention group
Group type: COMPARATOR
Intervention: Being excluded (Study 2)
Number of subjects: 143
Study 19278178 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15 mg/kg
Number of subjects: 154
Study 19278178 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.3 mg/kg
Number of subjects: 154
Study 19278178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 17216322 — intervention group
Group type: EXPERIMENTAL
Intervention: High spinal anesthesia (2.7 ml of 0.5% hyperbaric bupivacaine)
Number of subjects: 55
Study 17216322 — intervention group
Group type: COMPARATOR
Intervention: Low spinal anesthesia (1.5 ml of 0.5% hyperbaric bupivacaine)
Number of subjects: 55
Study 15577367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 100
Study 15577367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (150 mg)
Number of subjects: 100
Study 15577367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg) and Bupivacaine (150 mg)
Number of subjects: 100
Study 15577367 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 11378836 — intervention group
Group type: EXPERIMENTAL
Intervention: T102C 5-HT(2A) polymorphism in hypertensive subjects (female group)
Number of subjects: 342
Study 11378836 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 342
Study 9235679 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (dextran‐70, low molecular weight heparin, and graded elastic stockings) during the first week after operation
Number of subjects: 258
Study 9235679 — intervention group
Group type: COMPARATOR
Intervention: Clinical diagnostics by visiting doctors
Number of subjects: 258
Study 7965237 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 90‐minute interactive seminars
Number of subjects: 146
Study 7965237 — intervention group
Group type: COMPARATOR
Intervention: Usual clerkship goals (Control)
Number of subjects: 146
Study 3675514 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled exercise (five deep knee bends followed by five upward arm extensions with 5‐lb weights every 15 min)
Number of subjects: 0
Study 3675514 — intervention group
Group type: COMPARATOR
Intervention: No-exercise condition (sedentary)
Number of subjects: 0
Study 28452112 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention (n = 50)
Number of subjects: 99
Study 28452112 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (n = 49)
Number of subjects: 99
Study 28763548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (0.6-0.8 mg/kg/d; maximum 48 mg/d) for 2 months, followed by weaning over 4 to 6 months.
Number of subjects: 262
Study 28763548 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 2 months, followed by weaning over 4 to 6 months.
Number of subjects: 262
Study 25618178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian drilling with bipolar energy
Number of subjects: 126
Study 25618178 — intervention group
Group type: COMPARATOR
Intervention: Ovarian hyperstimulation with FSH + insemination + metformin
Number of subjects: 126
Study 22940159 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive visual-motor intervention (DVMI)
Number of subjects: 116
Study 22940159 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive supportive intervention (NDSI)
Number of subjects: 116
Study 20564075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil, doxorubicin, and cyclophosphamide with or without paclitaxel
Number of subjects: 42
Study 18219451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) applied to bilateral Hegu (LI4) and Neiguan (PC6) points, starting 30 min before analgesia induction to 24 h after operation.
Number of subjects: 60
Study 18219451 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS (Control)
Number of subjects: 60
Study 16825492 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets stored in plasma
Number of subjects: 168
Study 16825492 — intervention group
Group type: COMPARATOR
Intervention: Platelets stored in PAS II
Number of subjects: 168
Study 14659529 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline psychological measures during drug-free period
Number of subjects: 68
Study 14659529 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline catastrophizing
Number of subjects: 68
Study 14659529 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing activity in response to pain
Number of subjects: 68
Study 14659529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring pain sensations at baseline
Number of subjects: 68
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin (s.c. injection of 6300 anti-Xa units)
Number of subjects: 9
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA 300 mg o.d. from day 1-5)
Number of subjects: 9
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reviparin and ASA
Number of subjects: 9
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA 300 mg)
Number of subjects: 9
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin with ASA
Number of subjects: 9
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 9
Study 10759689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with ASA and reviparin
Number of subjects: 9
Study 8623941 — intervention group
Group type: EXPERIMENTAL
Intervention: Common facts presented via headphones (Group A, 29 patients)
Number of subjects: 58
Study 8623941 — intervention group
Group type: COMPARATOR
Intervention: Familiar or unfamiliar full names of fictitious people (Group B, 29 patients)
Number of subjects: 58
Study 1460166 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 216
Study 1460166 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 216
Study 30635887 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily single-dose triple therapy (esomeprazole 40 mg, tinidazole 1 g, levofloxacin 500 mg once-daily for 14 days)
Number of subjects: 212
Study 30635887 — intervention group
Group type: COMPARATOR
Intervention: Conventional triple therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg twice-daily for 14 days)
Number of subjects: 212
Study 30635887 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily single-dose triple therapy
Number of subjects: 212
Study 30635887 — intervention group
Group type: COMPARATOR
Intervention: Conventional triple therapy
Number of subjects: 212
Study 30635887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study 27233377 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous alternating therapy (CAT) with inhaled aztreonam (AZLI) and tobramycin inhalation solution (TIS)
Number of subjects: 90
Study 27233377 — intervention group
Group type: COMPARATOR
Intervention: Placebo/TIS
Number of subjects: 90
Study 24677394 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Navigation
Number of subjects: 62
Study 24677394 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study 22704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminex immunoassay
Number of subjects: 0
Study 22704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane-based ELISA
Number of subjects: 0
Study 22704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic ELISA
Number of subjects: 0
Study 22704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytometric bead assays (CBA)
Number of subjects: 0
Study 22704737 — intervention group
Group type: COMPARATOR
Intervention: ELISA (gold standard)
Number of subjects: 0
Study 19968808 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil bolus dose (3.1 mcg x kg(‐1) for group I, 3.7 mcg x kg(‐1) for group II, 3.0 mcg x kg(‐1) for group III)
Number of subjects: 64
Study 19968808 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil bolus dose (3.1-3.7 mcg x kg(‐1))
Number of subjects: 64
Study 19968808 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil ED(50)
Number of subjects: 64
Study 19968808 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil ED(95)
Number of subjects: 64
Study 19968808 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison
Number of subjects: 64
Study 19007075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatamp colloidal silver gelatin sponge
Number of subjects: 672
Study 19007075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 672
Study 16280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Firm polymer stent (Percuflex, group 1)
Number of subjects: 130
Study 16280829 — intervention group
Group type: COMPARATOR
Intervention: Soft polymer stent (Contour, group 2)
Number of subjects: 130
Study 16280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 14642512 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid to triceps transfer
Number of subjects: 9
Study 14642512 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps to triceps transfer
Number of subjects: 9
Study 10784479 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 10
Study 10784479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8970221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 24
Study 8970221 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 24
Study 1614047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose solution
Number of subjects: 33
Study 1614047 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.27% glucose solution
Number of subjects: 33
Study 1614047 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% glucose solution
Number of subjects: 33
Study 1614047 — intervention group
Group type: EXPERIMENTAL
Intervention: All glucose solutions (1.36%, 2.27%, 3.86%)
Number of subjects: 33
Study 6392282 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 100
Study 6392282 — intervention group
Group type: COMPARATOR
Intervention: metronidazole
Number of subjects: 100
Study 30654298 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 382
Study 30654298 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 382
Study 29112514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cold saline (CS) (4°C)
Number of subjects: 12
Study 29112514 — intervention group
Group type: COMPARATOR
Intervention: Intravenous room temperature saline (RS) (22°C)
Number of subjects: 12
Study 27567528 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-point awareness scale
Number of subjects: 0
Study 27567528 — intervention group
Group type: COMPARATOR
Intervention: Other scale lengths (not specified)
Number of subjects: 0
Study 24265104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered 1 hr before therapy sessions
Number of subjects: 22
Study 24265104 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hr before therapy sessions
Number of subjects: 22